The author of the article “It’s time to pull the plug on the new oral anticoagulants for nonvalvular atrial fibrillation” (BCMJ 2014;56:391-394 [10]) has corrected an error that appeared in Table 1 (edoxaban 60 mg was in the ENGAGE trial, not the RE-LY trial). The corrected version of the article is available online at bcmj.org.
Links
[1] https://bcmj.org/cover/december-2014
[2] https://bcmj.org/node/5263
[3] https://bcmj.org/sites/default/files/BCMJ_56_Vol10_pulsimeter_9_5.pdf
[4] https://bcmj.org/print/news/correction-new-oral-anticoagulants-nonvalvular-atrial-fibrillation
[5] https://bcmj.org/printmail/news/correction-new-oral-anticoagulants-nonvalvular-atrial-fibrillation
[6] http://www.facebook.com/share.php?u=https://bcmj.org/print/news/correction-new-oral-anticoagulants-nonvalvular-atrial-fibrillation&via=BCMedicalJrnl&tw_p=tweetbutton
[7] https://twitter.com/intent/tweet?text=Correction: New oral anticoagulants for nonvalvular atrial fibrillation&url=https://bcmj.org/print/news/correction-new-oral-anticoagulants-nonvalvular-atrial-fibrillation&via=BCMedicalJrnl&tw_p=tweetbutton&via=BCMedicalJrnl&tw_p=tweetbutton
[8] https://www.linkedin.com/sharing/share-offsite/?url=https://bcmj.org/print/news/correction-new-oral-anticoagulants-nonvalvular-atrial-fibrillation&via=BCMedicalJrnl&tw_p=tweetbutton
[9] https://bcmj.org/javascript%3A%3B
[10] https://bcmj.org/content/its-time-pull-plug-new-oral-anticoagulants-nonvalvular-atrial-fibrillation
[11] https://bcmj.org/modal_forms/nojs/webform/176
[12] https://bcmj.org/%3Finline%3Dtrue%23citationpop